{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:27:57Z","timestamp":1788964077942,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.atherosclerosis.2018.11.026","type":"journal-article","created":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T17:20:21Z","timestamp":1542216021000},"page":"51-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial"],"prefix":"10.1016","volume":"280","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5527-4821","authenticated-orcid":false,"given":"Matteo","family":"Pirro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8752-8278","authenticated-orcid":false,"given":"Daniela","family":"Francisci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Bianconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3216-4144","authenticated-orcid":false,"given":"Elisabetta","family":"Schiaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo R.","family":"Mannarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Barsotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Spinozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bagaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Baldelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib1","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1161\/CIRCULATIONAHA.107.189624","article-title":"Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy","volume":"118","author":"Currier","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/COH.0b013e328347876c","article-title":"Cardiovascular disease in HIV infection","volume":"6","author":"Palella","year":"2011","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1089\/met.2008.0096","article-title":"Human immunodeficiency virus and highly active antiretroviral therapy\u2013associated metabolic disorders and risk factors for cardiovascular disease","volume":"7","author":"Anuurad","year":"2009","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib4","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ecl.2014.06.003","article-title":"Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection","volume":"43","author":"Kelesidis","year":"2014","journal-title":"Endocrinol. Metab. Clin. North. Am."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/infdis\/jiv007","article-title":"Inflammation in chronic HIV infection: what can we do?","volume":"212","author":"Erlandson","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib6","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1097\/QAD.0b013e32832d3b85","article-title":"Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study","volume":"23","author":"Grunfeld","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/QAI.0b013e3182a97c17","article-title":"Pulse wave velocity as index of arterial stiffness in HIV-infected patients compared with a healthy population","volume":"65","author":"Echeverr\u00eda","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib8","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1086\/503261","article-title":"Endothelial function in HIV-infected persons","volume":"42","author":"Solages","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044454","article-title":"Inflammation, coagulation and cardiovascular disease in HIV-infected individuals","volume":"7","author":"Duprez","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2016.06.005","article-title":"A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients","volume":"111","author":"Banach","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/hrt.2004.056523","article-title":"Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: a randomized double blind crossover trial","volume":"92","author":"H\u00fcrlimann","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib12","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2352-3018(14)00032-0","article-title":"Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Lo","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib13","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2174\/1570161114666160106151652","article-title":"Lipid-lowering therapy in HIV-infected patients: relationship with antiretroviral agents and impact of substance-related disorders","volume":"14","author":"Bednasz","year":"2016","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.eimc.2014.03.014","article-title":"Rhabdomyolysis and severe hepatotoxicity due to a drug-drug interaction between ritonavir and simvastatin. Could we use the most cost-effective statin in all human immunodeficiency virus-infected patients?","volume":"32","author":"Bastida","year":"2014","journal-title":"Enferm. Infect. Microbiol. Clin."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.numecd.2016.11.122","article-title":"Joint position statement on \"nutraceuticals for the treatment of hypercholesterolemia\" of the Italian society of diabetology (SID) and of the Italian society for the study of arteriosclerosis (SISA)","volume":"27","author":"Pirro","year":"2017","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib16","doi-asserted-by":"crossref","first-page":"965","DOI":"10.5114\/aoms.2017.69326","article-title":"Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel","volume":"13","author":"Cicero","year":"2017","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.003","article-title":"A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: review of the clinical evidence","volume":"24","author":"Barrios","year":"2017","journal-title":"Atheroscler. Suppl."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40292-016-0163-2","article-title":"Effects of a combined nutraceutical on lipid pattern, glucose metabolism and inflammatory parameters in moderately hypercholesterolemic subjects: a double-blind, cross-over, randomized clinical trial, high","volume":"24","author":"Cicero","year":"2017","journal-title":"Blood. Press. Cardiovasc. Prev."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib19","doi-asserted-by":"crossref","first-page":"23587","DOI":"10.1038\/srep23587","article-title":"Effects of a nutraceutical combination on lipids, inflammation and endothelial integrity in patients with subclinical inflammation: a randomized clinical trial","volume":"6","author":"Pirro","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.phrs.2016.04.021","article-title":"The effects of a nutraceutical combination on plasma lipids and glucose: a systematic review and meta-analysis of randomized controlled trials","volume":"110","author":"Pirro","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.phanu.2013.02.003","article-title":"Nutraceutical combination (red yeast rice, berberine and policosanols) improves aortic stiffness in low-moderate risk hypercholesterolemic patients","volume":"1","author":"Pirro","year":"2013","journal-title":"PharmaNutrition"},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib22","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3945\/ajcn.2009.28137","article-title":"Effect of a dietary intervention and n-3 fatty acid supplementation on measures of serum lipid and insulin sensitivity in persons with HIV","volume":"90","author":"Woods","year":"2009","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0899-9007(01)00688-8","article-title":"A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia","volume":"18","author":"Keithley","year":"2002","journal-title":"Nutrition"},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib24","first-page":"30","article-title":"Policosanol for managing human immunodeficiency virus-related dyslipidemia in a medically underserved population: a randomized, controlled clinical trial","volume":"17","author":"Swanson","year":"2011","journal-title":"Altern. Ther. Health Med."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib25","article-title":"Probiotics reduce inflammation in antiretroviral treated, HIV-infected individuals: results of the \"Probio-HIV\" clinical trial","volume":"10","author":"d'Ettorre","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib26","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1001\/archinte.166.8.909","article-title":"Prognostic impact of prolonged ventricular repolarization in hypertension","volume":"166","author":"Schillaci","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib27","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.atherosclerosis.2011.05.010","article-title":"Large-artery stiffness: a reversible marker of cardiovascular risk in primary hyperparathyroidism","volume":"218","author":"Schillaci","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib28","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/HJH.0b013e328344da49","article-title":"Combined effects of office and 24-h blood pressure on aortic stiffness in human hypertension","volume":"29","author":"Schillaci","year":"2011","journal-title":"J. Hypertens."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib29","doi-asserted-by":"crossref","first-page":"924","DOI":"10.5551\/jat.13128","article-title":"Association of parathyroid hormone and 25-OH-vitamin D levels with arterial stiffness in postmenopausal women with vitamin D insufficiency","volume":"19","author":"Pirro","year":"2012","journal-title":"J. Atheroscler. Thromb."},{"issue":"2016","key":"10.1016\/j.atherosclerosis.2018.11.026_bib30","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the national cholesterol education program adult treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib32","first-page":"178","article-title":"Effects of a nutraceutical combination containing berberine (BRB), policosanol, and red yeast rice (RYR), on lipid profile in hypercholesterolemic patients: a meta-analysis of randomised controlled trials","volume":"28","author":"Mill\u00e1n","year":"2016","journal-title":"Clin. Investig. Arterioscler."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib33","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/cid\/ciw615","article-title":"Cardiovascular disease risk prediction in the HIV outpatient study","volume":"63","author":"Thompson-Paul","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib34","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/jcph.473","article-title":"Management of lipid disorders in patients living with HIV","volume":"55","author":"Myerson","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib35","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1086\/378131","volume":"37","author":"Dub\u00e9","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib36","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1468-1293.2007.00534.x","article-title":"European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV","volume":"9","author":"Lundgren","year":"2008","journal-title":"HIV. Med."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib37","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf, Accessed 6 January 2018."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib38","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1074\/jbc.M114.597229","article-title":"Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1\u03b1 protein expression through the ubiquitin-proteasome degradation pathway","volume":"290","author":"Dong","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib39","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1097\/QAD.0000000000001633","article-title":"Impact of protease inhibitors on circulating PCSK9 levels in HIV-infected antiretroviral-naive patients from an ongoing prospective cohort","volume":"31","author":"Boccara","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib40","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.atherosclerosis.2016.07.922","article-title":"Prediction of cardiovascular events with levels of proprotein convertase subtilisin\/kexin type 9: a systematic review and meta-analysis","volume":"252","author":"Vlachopoulos","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib41","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.jacc.2007.01.083","article-title":"Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis","volume":"49","author":"Kinlay","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1179\/1476830513Y.0000000106","article-title":"Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial","volume":"18","author":"Sanoobar","year":"2015","journal-title":"Nutr. Neurosci."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib43","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1017\/S0007114510005398","article-title":"Antioxidant effect of astaxanthin on phospholipid peroxidation in human erythrocytes","volume":"105","author":"Nakagawa","year":"2011","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib44","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3945\/ajcn.115.115477","article-title":"Astaxanthin has no effect on arterial stiffness, oxidative stress, or inflammation in renal transplant recipients: a randomized controlled trial (the XANTHIN trial)","volume":"103","author":"Coombes","year":"2016","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib45","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib46","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00149831-200412000-00009","article-title":"Attenuation of inflammation with short-term dietary intervention is associated with a reduction of arterial stiffness in subjects with hypercholesterolaemia","volume":"11","author":"Pirro","year":"2004","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib47","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2362.2004.01345.x","article-title":"Low-grade systemic inflammation impairs arterial stiffness in newly diagnosed hypercholesterolaemia","volume":"34","author":"Pirro","year":"2004","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib48","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.numecd.2006.02.009","article-title":"Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia","volume":"17","author":"Pirro","year":"2007","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib49","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000096747","article-title":"Cholesterol, lipids and arterial stiffness","volume":"44","author":"Wilkinson","year":"2007","journal-title":"Adv. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2337\/dc06-1075","volume":"30","author":"Samaras","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib51","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1186\/s12879-017-2626-z","article-title":"Cardiovascular risk and dyslipidemia among persons living with HIV: a review","volume":"9","author":"Maggi","year":"2017","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jacl.2013.11.003","article-title":"Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus","volume":"8","author":"Ruscica","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib53","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1097\/QAD.0000000000001642","article-title":"Dysfunctional high-density lipoprotein from HIV+ individuals promotes monocyte-derived foam cell formation in vitro","volume":"31","author":"Angelovich","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib54","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MOL.0000000000000382","article-title":"Inflammation, remodeling, and other factors affecting HDL cholesterol efflux","volume":"28","author":"Ronsein","year":"2017","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib55","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1194\/jlr.M073270","article-title":"AMPK activation enhances the anti-atherogenic effects of high density lipoproteins in apoE\u2212\/\u2212 mice","volume":"58","author":"Ang","year":"2017","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib56","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3389\/fphar.2018.01121","article-title":"Berberine ameliorates high glucose-induced cardiomyocyte injury via ampk signaling activation to stimulate mitochondrial biogenesis and restore autophagic flux","volume":"9","author":"Weijian","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib57","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40119-017-0092-8","article-title":"Elevated circulating PCSK9 concentrations predict subclinical atherosclerotic changes in low risk obese and non-obese patients","volume":"6","author":"T\u00f3th","year":"2017","journal-title":"Cardiol. Ther."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib58","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/met.2017.0027","article-title":"Association between plasma proprotein convertase subtilisin\/kexin type 9 and the presence of metabolic syndrome in a predominantly rural-based sub-saharan African population","volume":"15","author":"Paquette","year":"2017","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib59","doi-asserted-by":"crossref","first-page":"S337","DOI":"10.1016\/j.dsx.2017.03.012","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) and metabolic syndrome components among young adult females","volume":"11","author":"Hasan","year":"2017","journal-title":"Diabetes. Metab. Syndr."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib60","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1177\/2047487317724342","article-title":"PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans","volume":"24","author":"Baragetti","year":"2017","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib61","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.atherosclerosis.2014.07.010","article-title":"PCSK9 levels in abdominally obese men: association with cardiometabolic risk profile and effects of a one-year lifestyle modification program","volume":"236","author":"Arsenault","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib62","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2018.11.026_bib63","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1097\/QAD.0000000000001648","article-title":"Association of a 3' untranslated region polymorphism in proprotein convertase subtilisin\/kexin type 9 with HIV viral load and CD4+ levels in HIV\/hepatitis C virus coinfected women","volume":"31","author":"Kuniholm","year":"2017","journal-title":"AIDS"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018314886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915018314886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T01:04:32Z","timestamp":1662426272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915018314886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":63,"alternative-id":["S0021915018314886"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.11.026","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.11.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}